Price T Rowe Associates Inc Cytokinetics Inc Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,625,081 shares of CYTK stock, worth $123 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,625,081
Previous 3,164,945
17.06%
Holding current value
$123 Million
Previous $167 Million
26.11%
% of portfolio
0.01%
Previous 0.02%
Shares
17 transactions
Others Institutions Holding CYTK
# of Institutions
396Shares Held
122MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$688 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$558 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$504 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.89MShares$370 Million0.07% of portfolio
-
State Street Corp Boston, MA6.17MShares$289 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.41B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...